Cargando…

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients

BACKGROUND: Immune checkpoint inhibitors blocking programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have emerged as effective treatment options for cancer. However, immunotherapy is only effective in a subset of patients. Identifying effective biomarkers to predict the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Guanghui, Zhang, Xiao-Dong, Qu, Hu, Yao, Bing, Zhou, Yuxi, Xiang, Jianxing, Chen, Chunxiang, Hou, Ting, Chen, Kai, Xu, Junying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106035/
https://www.ncbi.nlm.nih.gov/pubmed/33987375
http://dx.doi.org/10.21037/atm-21-853
_version_ 1783689700212473856
author Gao, Guanghui
Zhang, Xiao-Dong
Qu, Hu
Yao, Bing
Zhou, Yuxi
Xiang, Jianxing
Chen, Chunxiang
Hou, Ting
Chen, Kai
Xu, Junying
author_facet Gao, Guanghui
Zhang, Xiao-Dong
Qu, Hu
Yao, Bing
Zhou, Yuxi
Xiang, Jianxing
Chen, Chunxiang
Hou, Ting
Chen, Kai
Xu, Junying
author_sort Gao, Guanghui
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors blocking programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have emerged as effective treatment options for cancer. However, immunotherapy is only effective in a subset of patients. Identifying effective biomarkers to predict the treatment response to PD-1/PD-L1 inhibitors remains an unmet clinical need. METHODS: This study retrospectively analyzed clinical information and genetic profiling results of 16,013 samples from Chinese patients with various cancer types in order to investigate the prevalence of CD274 (also known as PD-L1) amplification in various cancer types and its association with existing PD-1/PD-L1 biomarkers, including tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression. RESULTS: Amplification of CD274 was identified in 174 samples with an overall prevalence of 1.09% among all cancer types in the cohort. The prevalence of CD274 amplification in different cancer types and histological subtypes of lung cancer was varied, with cervical cancer having the highest prevalence. Distinct distributions of TMB, MSI, and PD-L1 expression between CD274-amplified and wild-type samples were observed in several cancer types as well as among different histological subtypes of lung cancer. CONCLUSIONS: Although CD274 amplification was only observed in a small proportion of patients, it demonstrated an association with TMB, MSI, and PD-L1 expression in several common cancer types. The molecular features of CD274 in different cancer types are heterogeneous. The role of CD274 amplification as a novel biomarker of PD-1/PD-L1 inhibitors remains to be characterized in future prospective clinical studies.
format Online
Article
Text
id pubmed-8106035
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81060352021-05-12 A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients Gao, Guanghui Zhang, Xiao-Dong Qu, Hu Yao, Bing Zhou, Yuxi Xiang, Jianxing Chen, Chunxiang Hou, Ting Chen, Kai Xu, Junying Ann Transl Med Original Article BACKGROUND: Immune checkpoint inhibitors blocking programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have emerged as effective treatment options for cancer. However, immunotherapy is only effective in a subset of patients. Identifying effective biomarkers to predict the treatment response to PD-1/PD-L1 inhibitors remains an unmet clinical need. METHODS: This study retrospectively analyzed clinical information and genetic profiling results of 16,013 samples from Chinese patients with various cancer types in order to investigate the prevalence of CD274 (also known as PD-L1) amplification in various cancer types and its association with existing PD-1/PD-L1 biomarkers, including tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression. RESULTS: Amplification of CD274 was identified in 174 samples with an overall prevalence of 1.09% among all cancer types in the cohort. The prevalence of CD274 amplification in different cancer types and histological subtypes of lung cancer was varied, with cervical cancer having the highest prevalence. Distinct distributions of TMB, MSI, and PD-L1 expression between CD274-amplified and wild-type samples were observed in several cancer types as well as among different histological subtypes of lung cancer. CONCLUSIONS: Although CD274 amplification was only observed in a small proportion of patients, it demonstrated an association with TMB, MSI, and PD-L1 expression in several common cancer types. The molecular features of CD274 in different cancer types are heterogeneous. The role of CD274 amplification as a novel biomarker of PD-1/PD-L1 inhibitors remains to be characterized in future prospective clinical studies. AME Publishing Company 2021-04 /pmc/articles/PMC8106035/ /pubmed/33987375 http://dx.doi.org/10.21037/atm-21-853 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Gao, Guanghui
Zhang, Xiao-Dong
Qu, Hu
Yao, Bing
Zhou, Yuxi
Xiang, Jianxing
Chen, Chunxiang
Hou, Ting
Chen, Kai
Xu, Junying
A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title_full A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title_fullStr A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title_full_unstemmed A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title_short A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
title_sort comprehensive pan-cancer analysis of cd274 gene amplification, tumor mutation burden, microsatellite instability, and pd-l1 expression in chinese cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106035/
https://www.ncbi.nlm.nih.gov/pubmed/33987375
http://dx.doi.org/10.21037/atm-21-853
work_keys_str_mv AT gaoguanghui acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT zhangxiaodong acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT quhu acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT yaobing acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT zhouyuxi acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT xiangjianxing acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT chenchunxiang acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT houting acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT chenkai acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT xujunying acomprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT gaoguanghui comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT zhangxiaodong comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT quhu comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT yaobing comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT zhouyuxi comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT xiangjianxing comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT chenchunxiang comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT houting comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT chenkai comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients
AT xujunying comprehensivepancanceranalysisofcd274geneamplificationtumormutationburdenmicrosatelliteinstabilityandpdl1expressioninchinesecancerpatients